Globus Medical Appoints New CFO

TL;DR

Globus Medical snagged NuVasive's ex-CFO, David Johnson, starting June 10th. Big move for their finance team.

AI Summary

Globus Medical, Inc. announced on June 5, 2024, the appointment of David C. Johnson as Chief Financial Officer, effective June 10, 2024. Johnson previously served as CFO of NuVasive, Inc. and brings extensive financial leadership experience in the medical device industry. This appointment follows the company's recent strategic initiatives and aims to strengthen its financial operations.

Why It Matters

The appointment of a new CFO can signal a shift in financial strategy or a focus on growth and operational efficiency, impacting investor confidence and the company's financial performance.

Risk Assessment

Risk Level: medium — Changes in key executive positions like CFO can introduce uncertainty regarding future financial strategies and operational execution.

Key Players & Entities

• Globus Medical, Inc. (company) — Registrant
• David C. Johnson (person) — Appointed Chief Financial Officer
• NuVasive, Inc. (company) — Former employer of new CFO
• June 5, 2024 (date) — Date of Report
• June 10, 2024 (date) — Effective date of CFO appointment

FAQ

Filing Documents

• gmed-20240605x8k.htm (8-K) — 109KB
• gmed-20240605xex10_1.htm (EX-10.1) — 541KB
• 0001562762-24-000163.txt ( ) — 820KB
• gmed-20240605.xsd (EX-101.SCH) — 2KB
• gmed-20240605_lab.xml (EX-101.LAB) — 12KB
• gmed-20240605_pre.xml (EX-101.PRE) — 11KB
• gmed-20240605x8k_htm.xml (XML) — 4KB

07. Submission of Matters to a Vote of Security Holders

Item 5.07. Submission of Matters to a Vote of Security Holders. The Annual Meeting was held on June 5, 2024. At the Annual Meeting, the stockholders voted on the following four proposals and cast their votes as described below. Proposal 1 The individuals listed below were each elected at the Annual Meeting to serve a three-year term on the Company's Board of Directors. Nominee For Withhold Broker Non-Vote David D. Davidar 263,717,947 59,470,766 6,372,297 James R. Tobin 256,480,132 66,708,581 6,372,297 Stephen T. Zarrilli 319,986,786 3,201,927 6,372,297 Daniel J. Wolterman 322,452,687 736,026 6,372,297 Proposal 2 Approval of the Amendment to the 2021 Equity Incentive Plan: For Against Abstain Broker Non-Vote 244,115,224 78,950,353 123,136 6,372,297 Proposal 3 Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2024. This proposal was approved. For Against Abstain Broker Non-Vote 329,276,382 252,325 32,303 0 Proposal 4 A non-binding advisory vote to approve the compensation of the Company's named executive officers, as described in the Company's definitive proxy statement on Schedule 14A filed with the Securities and Exchange Commission. This proposal was approved. For Against Abstain Broker Non-Vote 315,355,286 7,709,004 124,423 6,372,297

01. Financial Statements and Exhibits

Item 9.01. Financial Statements and Exhibits. (d) Exhibits Exhibit Number Description 10.1 2021 Equity Incentive Plan, as amended 104 Cover Page Interactive Data file (formatted in Inline XBRL)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. GLOBUS MEDICAL, INC. (Registrant) Dated: June 6, 2024 /s/ KELLY G. HULLER Kelly G. Huller Senior Vice President, General Counsel and Corporate Secretary

View Full Filing

View this 8-K filing on SEC EDGAR